H-Index & Metrics Top Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Medicine H-index 192 Citations 133,719 1,296 World Ranking 81 National Ranking 56

Research.com Recognitions

Awards & Achievements

2015 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Breast cancer

His primary areas of study are Breast cancer, Internal medicine, Oncology, Cancer and Surgery. His Breast cancer study integrates concerns from other disciplines, such as Cancer research and Metastasis. His research investigates the connection with Internal medicine and areas like Gynecology which intersect with concerns in Epidemiology.

His Oncology study incorporates themes from Retrospective cohort study, Pathology, Proportional hazards model, Hazard ratio and Survival analysis. His study ties his expertise on Odds ratio together with the subject of Cancer. His Surgery research is multidisciplinary, relying on both Gastroenterology and Disease.

His most cited work include:

  • PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients (1523 citations)
  • Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy (1509 citations)
  • Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation (1133 citations)

What are the main themes of his work throughout his whole career to date?

His main research concerns Internal medicine, Breast cancer, Oncology, Cancer and Chemotherapy. His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology and Surgery. The various areas that Gabriel N. Hortobagyi examines in his Surgery study include Taxane and Carcinoma.

His Breast cancer research incorporates elements of Cancer research, Pathology, Gynecology, Stage and Radiation therapy. His work carried out in the field of Oncology brings together such families of science as Neoadjuvant therapy, Clinical trial, Trastuzumab, Anthracycline and Disease. His studies in Cancer integrate themes in fields like Retrospective cohort study and Hazard ratio.

He most often published in these fields:

  • Internal medicine (71.29%)
  • Breast cancer (67.35%)
  • Oncology (58.83%)

What were the highlights of his more recent work (between 2012-2021)?

  • Internal medicine (71.29%)
  • Breast cancer (67.35%)
  • Oncology (58.83%)

In recent papers he was focusing on the following fields of study:

The scientist’s investigation covers issues in Internal medicine, Breast cancer, Oncology, Cancer and Cancer research. His Internal medicine study focuses mostly on Chemotherapy, Metastatic breast cancer, Proportional hazards model, Stage and Hazard ratio. Within one scientific family, Gabriel N. Hortobagyi focuses on topics pertaining to Surgery under Breast cancer, and may sometimes address concerns connected to Adverse effect.

In his study, Capecitabine and Neoadjuvant therapy is inextricably linked to Trastuzumab, which falls within the broad field of Oncology. The concepts of his Cancer study are interwoven with issues in Placebo, Cohort and Bioinformatics. His Cancer research research is multidisciplinary, incorporating perspectives in Immune checkpoint, Immunotherapy, Cancer cell, Cancer stem cell and Immunology.

Between 2012 and 2021, his most popular works were:

  • Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer (743 citations)
  • ESR1 ligand-binding domain mutations in hormone-resistant breast cancer (672 citations)
  • Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes (404 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Breast cancer

His primary areas of study are Internal medicine, Breast cancer, Oncology, Cancer and Proportional hazards model. Gabriel N. Hortobagyi has researched Internal medicine in several fields, including Gynecology and Surgery. His research integrates issues of Cancer research, Chemotherapy regimen, Survival rate, Retrospective cohort study and Stage in his study of Breast cancer.

His Oncology research incorporates themes from Neoadjuvant therapy, Trastuzumab, Inflammatory breast cancer, Disease and Cohort. His Cancer research includes themes of Incidence, PARP inhibitor and Bioinformatics. His study in Chemotherapy is interdisciplinary in nature, drawing from both Taxane and Estrogen receptor.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Top Publications

Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

Roman Rouzier;Charles M. Perou;W. Fraser Symmans;Nuhad Ibrahim.
Clinical Cancer Research (2005)

2296 Citations

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Yoichi Nagata;Keng Hsueh Lan;Xiaoyan Zhou;Ming Tan.
Cancer Cell (2004)

2033 Citations

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

Kathy S Albain;William E Barlow;Steven Shak;Gabriel N Hortobagyi.
Lancet Oncology (2010)

1610 Citations

Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation

Benjamin D. Smith;Grace L. Smith;Arti Hurria;Gabriel N. Hortobagyi.
Journal of Clinical Oncology (2009)

1530 Citations

Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

Aman U. Buzdar;Nuhad K. Ibrahim;Deborah Francis;Daniel J. Booser.
Journal of Clinical Oncology (2005)

1527 Citations

Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy

Henry M. Kuerer;Lisa A. Newman;Terry L. Smith;Fred C. Ames.
Journal of Clinical Oncology (1999)

1455 Citations

Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer

Frankie Ann Holmes;Ronald S. Walters;Richard L. Theriault;Aman U. Buzdar.
Journal of the National Cancer Institute (1991)

1310 Citations

Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone Metastases

Gabriel N. Hortobagyi;Richard L. Theriault;Lester Porter;Douglas Blayney.
The New England Journal of Medicine (1996)

1221 Citations

Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer

Massimo Cristofanilli;Daniel F. Hayes;G. Thomas Budd;Mathew J. Ellis.
Journal of Clinical Oncology (2005)

1209 Citations

The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine

Jeffrey S. Ross;Elzbieta A. Slodkowska;W. Fraser Symmans;Lajos Pusztai.
Oncologist (2009)

1181 Citations

Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking h-index is inferred from publications deemed to belong to the considered discipline.

If you think any of the details on this page are incorrect, let us know.

Contact us

Top Scientists Citing Gabriel N. Hortobagyi

Eric P. Winer

Eric P. Winer

Harvard University

Publications: 219

Massimo Cristofanilli

Massimo Cristofanilli

Northwestern University

Publications: 202

Mien Chie Hung

Mien Chie Hung

China Medical University

Publications: 200

Lajos Pusztai

Lajos Pusztai

Yale University

Publications: 190

Martine Piccart

Martine Piccart

Université Libre de Bruxelles

Publications: 178

Giuseppe Viale

Giuseppe Viale

European Institute of Oncology

Publications: 178

Clifford A. Hudis

Clifford A. Hudis

Memorial Sloan Kettering Cancer Center

Publications: 158

Kelly K. Hunt

Kelly K. Hunt

The University of Texas MD Anderson Cancer Center

Publications: 155

Thomas A. Buchholz

Thomas A. Buchholz

The University of Texas MD Anderson Cancer Center

Publications: 154

Jorge S. Reis-Filho

Jorge S. Reis-Filho

Memorial Sloan Kettering Cancer Center

Publications: 148

Robert E. Coleman

Robert E. Coleman

University of Sheffield

Publications: 139

Henry Mark Kuerer

Henry Mark Kuerer

The University of Texas MD Anderson Cancer Center

Publications: 137

Sibylle Loibl

Sibylle Loibl

Goethe University Frankfurt

Publications: 133

Giuseppe Curigliano

Giuseppe Curigliano

European Institute of Oncology

Publications: 131

Hope S. Rugo

Hope S. Rugo

University of California, San Francisco

Publications: 129

Something went wrong. Please try again later.